Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of olezarsen in severe hypertriglyceridemia
2021-002192-19Phase 3Active
- Sponsor
- Ionis Pharmaceuticals
- Start
- Nov 2021
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertriglyceridemia and endogenous hypertriglyceridemia comparing olezarsen arm with placebo arm (2 arms). Primary endpoint: Percent change in fasting triglycerides at Month 6. Started Nov 2021; status: active.
02
Drugs
olezarsen
03
Conditions
hypertriglyceridemiaendogenous hypertriglyceridemia
Beyond the preview
Go deeper on 2021-002192-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002192-19.